Plasma (p) VEGF-A and VEGFR-2 biomarker (BM) results from the BEATRICE phase III trial of bevacizumab (BEV) in triple negative early breast cancer (BC) - Carmeliet, P; Pallaud, C; Deurloo, R J (Cancer Res, 2012)
et al.